← All claims

Metabolic & Cardiometabolic

statins increases new-onset type 2 diabetes

In plain terms: Do statins increase the risk of developing type 2 diabetes?

Strong support Metabolic & Cardiometabolic

Part of: 💊 statins

RefutedContestedStrong support
consensus score 0.90

Yes, a real but modest effect: meta-analyses show roughly a 9-12% relative increase in new-onset diabetes, dose-dependent, and far outweighed by cardiovascular benefit in indicated patients.

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: All trials, pooled (Meta-analysis)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

7 support 0 contradict 0 tested null 1 mixed · 8 sources, 7 independent groups

The evidence (8)

SourceGradeStanceQualityFinding
Preiss
2011 · JAMA
meta-analysis supports high Meta-analysis of 5 trials (32,752): intensive-dose vs moderate-dose statins raised new-onset diabetes (OR 1.12), establishing dose-dependence of the diabetes signal.
Navarese
2013 · Am J Cardiol
meta-analysis supports high Network meta-analysis of 17 RCTs (113,394 patients) found statins increased new-onset diabetes in a type- and dose-dependent manner (highest with rosuvastatin/atorvastatin).
Li
2025 · Cardiovasc Drugs Ther
meta-analysis supports moderate Meta-analysis of statin adverse reactions across diseases quantified new-onset diabetes among the significant class effects.
Thakker
2016 · Pharmacoepidemiol Drug Saf
meta-analysis supports moderate Network meta-analysis of RCTs confirmed a significant association between statin therapy and incident diabetes.
Sattar
2010 · Lancet
meta-analysis supports high Collaborative meta-analysis of 13 trials (91,140 participants): statins raised new-onset diabetes 9% (OR 1.09); ~1 extra case per 255 patient-years — modest and outweighed by CV benefit.
Ridker 2008 (JUPITER)
venue: N Engl J Med · N Engl J Med
RCT supports moderate JUPITER: rosuvastatin showed a small but significant increase in physician-reported new-onset diabetes versus placebo, an early signal later confirmed by meta-analysis.
Albawa'neh
2025 · Ann Med
meta-analysis mixed moderate Systematic review noting statins increase new-onset T2DM while assessing ezetimibe; an independent contemporary confirmation of the statin-diabetes signal.
Naci
2013 · Circ Cardiovasc Qual Outcomes
meta-analysis supports high Study-level network meta-analysis of 135 RCTs (246,955 participants) found statins as a class raised diabetes risk, with heterogeneity between individual agents.

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.